drugset / Trial / NCT06488950
A Study of TIL in Advanced Solid Tumors (DFGD)
Phase 0
Recruiting
30 enrolled
Shanghai Juncell Therapeutics
Eastern Hepatobiliary Surgery Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs and gene-edited TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Timeline
- Start
- 2023-04-01
- Primary completion
- 2026-06-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GC203 TIL | Cell therapy | — | Intravenous |
| Subject | autologous TILs | Cell therapy | — | Intravenous |